Skip to main content

  • Alvimedica announces the approval for its Cre8™ & Cre8™ EVO DES to be implanted with just 1month DAPT duration when clinically indicated.

    Alvimedica announces the approval for its Cre8™ & Cre8™ EVO DES to be implanted with just 1month DAPT duration when clinically indicated.

  • Alvimedica announces the approval for its Cre8™ & Cre8™ EVO DES to be implanted with just 1month DAPT duration when clinically indicated.

    July 30, 2019 - ALVIMEDICA announces to have received the CE regulatory approval for its Cre8™ & Cre8™ EVO Drug-Eluting Stents (DES) to be implanted with just 1month of Dual AntiPlatelet Therapy (DAPT) duration when clinically indicated.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details